Exelixis (EXEL) Cash from Restructuring (2010 - 2025)

Exelixis (EXEL) recorded quarterly Cash from Restructuring of $153000.0 in Q1 2025, up 17.69% quarter-over-quarter from $130000.0 in Q2 2016.

Exelixis (EXEL) Cash from Restructuring (2010 - 2025) Analysis & Trends

Exelixis' Cash from Restructuring history runs 8 years deep, the most recent figure standing at $153000.0 for Q1 2025.

In Q1 2025, Cash from Restructuring changed N/A year-over-year to $153000.0; the TTM figure through Jan 2026 stood at $283000.0 (up 136.56% YoY), while the FY2025 annual figure was $64.4 million, changed N/A from the prior year.
Cash from Restructuring was $153000.0 for Q1 2025 at Exelixis, up from $130000.0 in the prior quarter.
In the past five years, Cash from Restructuring ranged from a high of $153000.0 in Q1 2025 to a low of $153000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Exelixis	13.71 Bn	12.93 Bn	590.86 Mn

Download Data